CALCILYTIX THERAPEUTICS
Calcilytix is investigating encaleret, a small molecule antagonist of the CaSR, as a potential therapeutic for hypoparathyroidism and ADH1. The CaSR is a G-protein-coupled receptor for which extracellular calcium is the primary ligand. The major physiologic role of the CaSR is to function conceptually as a ‘calciostat’ and maintain serum calcium levels by regulating the release of PTH and calcium reabsorption.
CALCILYTIX THERAPEUTICS
Social Links:
Industry:
Health Care
Founded:
2015-01-01
Address:
San Francisco, California, United States
Country:
United States
Website Url:
http://www.calcilytix.com
Total Employee:
11+
Status:
Active
Email Addresses:
[email protected]
Similar Organizations
Context Therapeutics
Context Therapeutics is a clinical-stage biopharmaceutical company.
Official Site Inspections
http://www.calcilytix.com Semrush global rank: 4.43 M Semrush visits lastest month: 2.49 K
- Host name: 141.193.213.10
- IP address: 141.193.213.10
- Location: United States
- Latitude: 37.751
- Longitude: -97.822
- Timezone: America/Chicago
More informations about "Calcilytix Therapeutics"
Calcilytix Therapeutics - Crunchbase Company Profile …
Calcilytix is investigating encaleret, a small molecule antagonist of the CaSR, as a potential therapeutic for hypoparathyroidism and ADH1. The CaSR is a G …See details»
Calcilytix Company Profile | Management and Employees List
Calcilytix Therapeutics, an affiliate of BridgeBio Pharma, is a clinical-stage biopharmaceutical company focused on developing a targeted therapy for disorders of calcium homeostasis. Our …See details»
Meet Our Partners | HypoPARAthyroidism Association
Bridgebio/Calcilytix. Calcilytix Therapeutics is a clinical-stage biopharmaceutical company based in California, USA. We are an affiliate of BridgeBio Pharma, whose goal is to create life …See details»
Bridgebio/Calcilytix :: HypoPARAthyroidism Association …
Calcilytix is investigating Encaleret as a potential treatment for ADH1 (autosomal dominant hypocalcemia type 1), a genetic cause of hypoPARAthyroidism. Encaleret is an investigational, orally-administered small molecule designed to …See details»
Calcilytix Therapeutics, Inc. - Drug pipelines, Patents, Clinical ...
Nov 2, 2023 The next steps include a review with the FDA as Calcilytix defines a larger Phase III confirmatory study ahead. Collaborate. 100 Deals associated with Calcilytix Therapeutics, Inc. …See details»
Calcilytix Therapeutics Overview | SignalHire Company Profile
Calcilytix Therapeutics, an affiliate of BridgeBio Pharma, is a clinical-stage biopharmaceutical company focused on developing a targeted therapy for disorders of calcium homeostasis. ...See details»
Calcilytix Therapeutics - Contacts, Employees, Board Members, …
Calcilytix is a clinical-stage biopharmaceutical company. AI Content may contain mistakes and is not legal, financial or investment advice.See details»
Calcilytix - Overview, News & Similar companies | ZoomInfo.com
Who is Calcilytix. Calcilytix Therapeutics, an affiliate of BridgeBio Pharma, is a clinical-stage biopharmaceutical company focused on developing a targeted therapy f or disorders of …See details»
what is autosomal dominant hypocalcemia type 1?
What is autosomal dominant hypocalcemia type 1?. Autosomal dominant hypocalcemia type 1 (ADH1) is a common form of genetic hypoparathyroidism. Gain-of-function variants in the calcium-sensing receptor gene (CASR ) are …See details»
Calcilytix Therapeutics - VentureRadar
Calcilytix is investigating encaleret, a small molecule antagonist of the CaSR, as a potential therapeutic for hypoparathyroidism and ADH1.See details»
Director/Sr. Director, Program Management | San Francisco Bay …
Apply Now. About Calcilytix & BridgeBio Pharma. Calcilytix Therapeutics, an affiliate of BridgeBio Pharma, is developing encaleret (CLTX-305), a negative allosteric modulator of the calcium …See details»
Calcilytix DetectHypopara Sponsored Testing Program
In partnership with Calcilytix Therapeutics (a BridgeBio Company), this DetectHypoparaâ„¢ Genetic Testing Program provides US and Canada physicians with access to no-cost genetic …See details»
FDA Fast Track Designation for Encaleret | BridgeBio
Jun 1, 2021 “Balancing near-normal blood and avoiding excess urinary calcium is a daily struggle for patients with ADH1 as the range of symptoms produced by the highs and lows of …See details»
12520 Preliminary Findings From An Ongoing Open-label Phase 2 …
Official websites use .gov A .gov website belongs to an official government organization in the United States.See details»
A Phase 2B, Open-Label, Dose-Ranging Study of Encaleret (CLTX …
A .gov website belongs to an official government organization in the United States . Secure .gov websites use HTTPS ... began in September 2020 with topline results expected in 2021. This …See details»
Fellowship in Industry Program — Calcilytix - University of the Pacific
About Calcilytix Calcilytix is a clinical-stage biopharmaceutical company focused on developing a targeted therapy for disorders of calcium homeostasis. Our product candidate, encaleret, is an …See details»
CALIBRATE: A phase 3, randomized, open-label study evaluating …
Autosomal dominant hypocalcemia type 1 (ADH1), caused by pathogenic gain-of-function calcium-sensing receptor gene (CASR) variants, is characterized by low parathyroid hormone …See details»
Effects of Encaleret (CLTX-305) on Mineral Physiology in …
Intramural Research Program and BridgeBio affiliate Calcilytix Therapeutics, Inc. •Encaleret is currently under clinical development, and its safety and efficacy have not been evaluated by …See details»
BridgeBio Pharma’s Calcilytix Therapeutics Initiates Phase 2 Study …
Sep 21, 2020 * Topline proof-of-concept results in ADH1 anticipated in 2021 * Currently, there are no approved therapies for ADH1PALO ALTO, Calif., Sept. 21, 2020 (GLOBE NEWSWIRE) …See details»
Encaleret - BridgeBio Pharma - AdisInsight - Springer
13 Jan 2025 Calcilytix Therapeutics completes enrolment in the phase III CALIBRATE trial for Hypocalcaemia (Treatment-experienced, In adolescents, In adults) in USA, Australia, Czech …See details»